Drug intelligence / Profile preview

Taiqi Peiyuan Granule

Development stage: Unknown
Lead developer: Fourth Affiliated Hospital of Xinjiang Medical University
Administration: Oral

Overview

Taiqi Peiyuan Granule is a Traditional Chinese Medicine (TCM) formulation developed for the treatment of immune dysfunction, particularly in the context of HIV/AIDS. It is currently being evaluated in clinical trials as an adjunctive therapy to Antiretroviral Therapy (ART) for patients experiencing incomplete immune reconstruction, characterized by persistently low CD4+ T-cell counts despite viral suppression. The granule is designed to tonify Qi and support the body's Original Qi (Yuan Qi), thereby enhancing the proliferation and function of immune cells. It is primarily associated with research conducted at the Fourth Affiliated Hospital of Xinjiang Medical University.

Brand names: Taiqi Peiyuan Granule
Other names: Taiqi Peiyuan Keli

Beyond the preview

Go deeper on Taiqi Peiyuan Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taiqi Peiyuan Granule.

Explore the full profile